# Entera Bio Ltd. (ENTXW) — capital_raise/private_placement [expired]
Source: SEC API (secapi.ai) · situation sit_4a1a29baec26503e04fc · retrieved 2026-08-12T21:28:51.615Z

## Overview
Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies using its proprietary N-Tab platform, with lead candidate EB613 (oral PTH(1-34)) in development as the first oral anabolic tablet for postmenopausal women with osteoporosis.

Entera Bio Ltd. announced an oversubscribed private placement that provided gross proceeds of approximately $275.0 million, led by existing investor BVF Partners L.P. with participation from new institutional healthcare investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management. Upon closing in July 2026, BVF was granted the right to designate two directors to the Company's board. The net proceeds are anticipated to fully support the Phase 3 registrational program of EB613 through anticipated NDA submission to the FDA, advance EB612 into the clinic in collaboration with OPKO, and extend the Company's cash runway into 2030.

## Terms
- Counterparty: BVF Partners L.P. and other institutional healthcare investors · Deal value: $275.0M · Consideration: cash · Stake: 9.99% · Price/share: $2.04

## Key dates
- Announced 2026-08-04 · Expired 2026-07-28

## Timeline
- 2026-07-28 · 8-K (0001178913-26-003617): 8-K - Entera Bio Ltd. — *Entera Bio Ltd. is a biopharmaceutical company developing oral delivery technologies for biologics; its lead candidate EB613 is in phase 3 development for postmenopausal osteoporosis.* Entera Bio Ltd. completed a private placement on July 28, 2026, issuing 122,961,215 ordinary shares and 11,842,695 pre-funded warrants for aggregate proceeds of approximately $275.0 million at $2.04 per ordinary share. The purchasers, including funds affiliated with BVF Partners L.P., received the right for BVF to designate two directors to the company's board, with such designation rights subject to BVF maintaining specified ownership thresholds (75% for two designees, 50% for one designee, and 10% of outstanding shares to maintain any designation rights). The company intends to use net proceeds to support activities related to initiation of its phase 3 registrational study of EB613 in postmenopausal women with osteoporosis and for general working capital and corporate purposes.
  https://www.sec.gov/Archives/edgar/data/1638097/0001178913-26-003617.txt
- 2026-08-04 · SCHEDULE 13D (0000921895-26-001957): SCHEDULE 13D - Entera Bio Ltd. — *EB613 is intended to provide an oral anabolic treatment earlier in an osteoporosis patient's journey to increase skeletal mass, reduce the risk of fracture, limit the disease progression, and decrease disability and mortality.* On July 26, 2026, Entera Bio Ltd. entered into a Securities Purchase Agreement with institutional and accredited investors, including BVF Partners L.P. and affiliated reporting persons, for a private placement of an aggregate of 134,803,910 ordinary shares (or pre-funded warrants in lieu thereof) at $2.04 per share for aggregate proceeds of approximately $275.0 million. The July Private Placement closed on July 28, 2026, with the issuer delivering 122,961,215 shares and 11,842,695 July Pre-Funded Warrants to all purchasers, including 14,627,893 shares and 11,842,695 July Pre-Funded Warrants to the BVF reporting persons. Effective as of the closing date, the issuer granted the reporting persons the right to designate two directors to the board of directors, subject to applicable legal and Nasdaq requirements, with the designation right reducing to one director if the reporting persons' ownership falls below 75% of the securities acquired in the placement, and terminating entirely if ownership falls below 50% or if beneficial ownership falls below 10% of outstanding shares.
  https://www.sec.gov/Archives/edgar/data/1638097/0000921895-26-001957.txt
- 2026-08-07 · 8-K (0001178913-26-003946): 8-K - Entera Bio Ltd. — *Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies using its proprietary N-Tab platform, with lead candidate EB613 (oral PTH(1-34)) in development as the first oral anabolic tablet for postmenopausal women with osteoporosis.* Entera Bio Ltd. announced an oversubscribed private placement that provided gross proceeds of approximately $275.0 million, led by existing investor BVF Partners L.P. with participation from new institutional healthcare investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management. Upon closing in July 2026, BVF was granted the right to designate two directors to the Company's board. The net proceeds are anticipated to fully support the Phase 3 registrational program of EB613 through anticipated NDA submission to the FDA, advance EB612 into the clinic in collaboration with OPKO, and extend the Company's cash runway into 2030.
  https://www.sec.gov/Archives/edgar/data/1638097/0001178913-26-003946.txt

## Citations
- 0001178913-26-003617 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000117891326003617
- 0000921895-26-001957 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000092189526001957
- 0001178913-26-003946 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000117891326003946